{
    "clinical_study": {
        "@rank": "35086", 
        "arm_group": [
            {
                "arm_group_label": "Raltitrexed plus Docetaxel", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Docetaxel", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in\n      subjects with Gastric Cancer.The purpose of this study is to compare the activity of\n      Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with\n      gastric carcinoma by estimating progression free survival (PFS) in each treatment arm."
        }, 
        "brief_title": "A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed informed consent form\n\n          2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;\n\n          3. Histologically or cytologically confirmed gastric cancer;\n\n          4. The first-line chemotherapy failure (required containing 5-fluorouracil)\n\n          5. At least have one measurable disease(according to RECIST, Response Evaluation\n             Criteria in Solid Tumors )\n\n          6. Life expectancy of at least 3 months;\n\n        Exclusion Criteria:\n\n          1. Received any prior treatment including Raltitrexed;\n\n          2. Active or uncontrolled infection;\n\n          3. Concurrent treatment with an investigational agent or participation in another\n             therapeutic clinical trial;\n\n          4. Pregnant or lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836120", 
            "org_study_id": "HBTH103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltitrexed plus Docetaxel", 
                "description": "Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d\n1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)", 
                "intervention_name": "Raltitrexed plus Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Docetaxel", 
                "description": "Docetaxel  (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Raltitrexed", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "second-line chemotherapy", 
            "Raltitrexed"
        ], 
        "lastchanged_date": "April 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050011"
                }, 
                "name": "Hebei Tumor Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: State Food and Drug Adminstration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "1 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Hebei Tumor Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Tumor Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}